Sett

Market position

Positioned as an alternative to nicotine pouch brands such as Zyn within the oral pouch and focus/energy supplement category; customer reviews on its site frame the product as a substitute for nicotine pouches.

Sett positions its pouches as a first-of-its-kind nicotine alternative combining a proprietary receptor-active compound with L-theanine, rather than flavored nootropic pouches without a nicotine-like mechanism, and emphasizes formulation input from physicians and human-performance specialists.

Technology

Ceretine, a synthetic alkaloid produced through a proprietary process of modifications to nicotinic acids (B-vitamins). The company says the compound originated from nicotine-alternative research conducted by tobacco companies in the 1980s that was later shelved, which its team revisited before running independent trials and testing more than 15 formulations. Sett reports in vitro and in vivo toxicity testing indicating the compound is non-carcinogenic and non-mutagenic with a toxicity profile comparable to nicotine, and receptor-binding studies showing an nAChR interaction pattern close to nicotine but with lower affinity for the α6 subtype, which the company associates with dependence. Additional studies are described as underway, with a stated long-term goal of clinically demonstrating advantages over nicotine on focus, mood and wellbeing.

Go-to-market

Online direct sales through getsett.co with subscription and bundle offers, supported by customer-review social proof, a named scientific and advisory board, and third-party recognition such as a 2025 Wellworthy award.

Consumers who use nicotine pouches or vapes for productivity, focus and energy — including current Zyn users and people attempting to reduce or quit nicotine — as well as performance-oriented professionals and athletes.

Geography

Sells in the United States with shipping in 3-7 business days, excluding Indiana due to a state law on non-nicotine products making nicotine-like claims; manufacturing is described as spanning the USA, Sweden and Denmark, with Ceretine produced in a US facility.

Risks & controversies

The product carries a warning that it may be addictive, and the company acknowledges Ceretine acts on the same receptors as nicotine and therefore carries some potential for dependence. Products may contain trace nicotine from shared manufacturing lines. State-level regulation already blocks sales in Indiana. Efficacy and safety claims rest on company-reported testing, with further clinical studies described as still underway.